A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules
Status:
Completed
Trial end date:
2019-03-10
Target enrollment:
Participant gender:
Summary
This is a Phase I, single-center, open-label, randomized,two-way crossover,
propofol-controlled, two-stage study evaluating the safety and
pharmacokinetics/pharmacodynamics of IV maintenance dose and IV single loade dose plus
maintenance dose of HSK3486 emulsion for injection in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Sichuan Haisco Pharmaceutical Group Co., Ltd Sichuan Haisco Pharmaceutical Group Co., Ltd.